Boostershots could reduce hospitalization rates in Europe by at least 500,000 patients, according to the European Union’s (EU) public health agency.
European Center for Disease Prevention and Control (ECDC) announced on January 27 statement “Current intake of booster doses achieved by early January could reduce future hospital admissions to Omicron Hospital by 500,000.” [to] 800,000 inches in EU / EEAEuropean Economic Area).
The ECDC figures cover the blocks of 27 EU countries and the EEA, which consists of Iceland, Liechtenstein and Norway. The EEA will consolidate three countries with blocks of 27 countries into a regional trading organization that follows the same rules, giving goods and travelers the freedom to move within the EEA in an open and competitive environment.
According to health agencies, uptake of primary COVID-19 vaccination in the EU / EEA has been “slowly increasing”, reaching 70% this week. On the other hand, booster shot uptake is increasing “more rapidly”, with 50% of adults in the EU / EEA already receiving doses.
“Extending the booster program to all previously vaccinated individuals can further reduce hospitalizations by another 300,000. [to] 500,000, “said the ECDC.
According to health agencies, cases of relatively mild Omicron variants in Europe are “spreading at unprecedented rates and intensities,” and the overall infection rate reported is CCP (Chinese Communist Party) virus A pandemic almost two years ago.
The EU’s Health and Food Safety Commission, Stella Kiriyakides, said authorities must remain vigilant for the detection of potential future CCP virus variants, although the peak of infection appears to have recently reached. He added that the pandemic is not over.
Early data on boosters against Omicron show that much of the lost protection has been restored, but protection against both infections and serious illnesses declines again within a few weeks.
Researchers at the US Centers for Disease Control and Prevention (CDC) and other medical institutions said: Research The efficacy of the two most preferred COVID-19 vaccines, Pfizer and Modana, has been dramatically reduced against both Omicron infections and hospitalizations in the United States, and protection for those who received a second dose 6 months ago. It dropped to 38%. ..
Efficacy for hospitalization was also reduced by 9% in those who completed the primary regimen within 6 months of admission, and nearly a quarter (57%) in those who were more than 6 months after the second dose of the first regimen. (Reduced to).
In addition, the researchers found that the vaccine provided little protection against infection.
“These findings provide evidence that the triple dose schedule is protective and that booster immunization is more protective than the primary series alone, but is significantly higher. [odds ratio] Omicron suggests that the booster effect is less protective against Omicron than Delta, “the researchers said.
The Epoch Times reporter Zachary Stever contributed to this report.
from NTD News